Flavopiridol (L86-8275): Selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells

Clinical Cancer Research

Volumn 3, Issue 2, 1997, Pages 273-279

  Drees, Markus ^a   Dengler, Wolfgang A ^a   Roth, Thomas ^a   Labonte, Heike ^a   Mayo, Joseph ^b   Malspeis, Louis ^b   Grever, Michael ^b   Sausville, Edward A ^b   Fiebig, Heinz H ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLAVONE DERIVATIVE; FLAVOPIRIDOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOMA; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; COLONY-FORMING UNITS ASSAY; DRUG SCREENING ASSAYS, ANTITUMOR; FLAVONOIDS; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PIPERIDINES; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0031019034     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Boyd, M. R. Status of the National Cancer Institute preclinical antitumor drug discovery screen: implications for selection of new agents for clinical trial. In: V. T. De Vita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology Update, Vol. 3, No. 10, pp. 1-12, Philadelphia: Lippincott, 1989.
2. Monks, A., Scudiero, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., Gray-Goodrich, M., Campbell, H., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Mayo, J., and Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst., 83: 757-766, 1991.
3. Grever, M. R., and Chabner, B. A. Cancer drug discovery and development. In: V. T. Rosenberg, S. Hellman, and S. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Vol. 1, pp. 328-339. Philadelphia: Lippincott, 1992.
4. Langdon, P. S., and Smyth, J. F. Studies in tumor cell biology. In: E. Boven and B. Winograd (eds.), The Nude Mice in Oncology Research, pp. 104-116. Boca Raton, FL: CRC Press, 1991.
5. Fiebig, H. H., Berger, D. P., Dengler, W. A., Wallbrecher, E., and Winterhalter, B. R. Combined in vitro/in vivo test procedure with human tumor xenografts for new drug development. Contrib. Oncol., 42: 321-351, 1992.
6. Fiebig, H. H. Comparison of tumor response in nude mice and in the patients. In: B. Winograd, M. J. Peckham, and H. M. Pinedo (eds.), Human Tumor Xenografts in Anticancer Drug Development, pp. 25-30. Berlin: Springer Verlag, 1983.
7. Fiebig, H. H., Schmid, J. R., Bieser, W., Henss, H., and Lohr, G. W. Colony assay with human tumor xenografts, murine tumors and human bone marrow. Potential for anticancer drug development. Eur. J. Cancer, 23: 937-948, 1987.
8. Naik, R. G., Kattige, S. L., Bhat, S. V., Alreja, B., de Souza, N. J., and Rupp, R. H. An anti-inflammatory cum immunomodulatory piperidinylbenzopyranone from Dysoxylum binectariferum: isolation, structure and total synthesis. Tetrahedron, 44: 2081-2086, 1988.
9. Naik, R. G. (Hoechst A. G.) European patent EP366061. Japanese patent JP90178225. German patent DE3836676. Vol. 2, May 1990.
10. Czech, J., Hoffmann, D., and Sedlacek, H. H. Antitumoral activity of L86-8275 on in vitro and in vivo model systems. Fourth International Congress on Hormones and Cancer. Amsterdam, 1991.
11. Sedlacek, H. H., Hoffmann, D., Czech, J., Cenek, K., Seemann, G., Güssow, D., and Bosslet, K. The change in research for the therapy of tumors. Chimia, 45: 311-316, 1991.
12. Kandaswami, C., Perkins, E., Drzewiecki, G., Soloniuk, D. S., and Middleton, E., Jr. Differential inhibition of human squamous cell carcinoma, gliosarcoma and embryonic fibroblast-like lung cells in culture by plant flavonoids. Anticancer Drugs, 3: 525-530, 1992.
13. Akiyama, T., and Ogawara, H. Use and specificity of genistein as inhibitor of protein tyrosine kinases. Methods Enzymol., 201: 362-370, 1991.
14. Suolinna, E. M., Buchsbaum, R. N., and Racker, E. The effect of flavonoids on aerobic glycolysis and growth of tumor cells. Cancer Res., 35: 1865-1872, 1975.
15. Chang, C. J., and Geahlen, R. L. Protein-tyrosine kinase inhibition: mechanism based discovery of antitumor agents. J. Nat. Prod., 55: 1529-1560, 1992.
16. Hagiwara, M., Inoue, S., Tanaka, T., Nunoki, K., Ito, M., and Hidaka, H. Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinases. Biochem. Pharmacol., 37: 2987-2992, 1988.
17. Hofmann, J., Fiebig, H. H., Winterhalter, B. R., Berger, D. P., and Grunicke, H. Enhancement of the antiproliferative activity of cis-diaminedichloroplatinum(II) by quercetin. Int. J. Cancer, 45: 536-539, 1990.
18. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M., and Fukami, Y. Genistein, a specific inhibitor of tyrosine specific protein kinases. J. Biol. Chem., 262: 5592-5595, 1987.
19. cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Biochem. Pharmacol., 46: 1831-1840, 1993.
20. Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E. A., and Worland, P. J. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun., 207: 589-595, 1994.
21. Losiewicz, M. D., Carlson, B. A., Sausville, E. A., Naik, R. G., Narayanan, V. L., and Worland, P. J. Inhibition of CDK2 by flavopiridol and structural analogs. Proc. Am. Assoc. Cancer Res., 36: 35, 1995.
22. 1-S phase block in MDA MB 468 breast carcinoma cells with deregulation of CDK2. Proc. Am. Assoc. Cancer Res., 36: 35, 1995.
23. 1 phase progression: cycling on cue. Cell, 79: 551-555, 1994.
24. Kaur, G., Stettler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., and Sausville, E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst., 84: 1736-1740, 1992.
25. Fiebig, H. H., Widmer, K. H., Fiedler, L., Wittekind, C., and Löhr, G. W. Development and characterization of 51 human tumor models for large bowel, stomach and esophageal cancers. Dig. Surg., 1: 225-235, 1984.
26. Berger, D. P., Winterhalter, B. R., and Fiebig, H. H. Establishment and characterization of human tumor xenografts in thymus aplastic nude mice. Contrib. Oncol., 42: 23-46, 1992.
27. Fiebig, H. H., and Von Kleist, S. Carcinoembryonic antigen (CEA) in human colorectal cancers growing subcutaneously in nude mice. J. Cancer Res. Clin. Oncol., 105: 238-242, 1983.
28. Furtwängler, I., Fiebig, H. H., Berger, D. P., and Wittekind, C. Immunohistochemical characterization of human tumor xenografts established in nude mice. Contrib. Oncol., 42: 148-151, 1992.
29. Fiebig, H. H., and Berger, D. P. Preclinical phase II trials. In: E. Boven and W. Winograd (eds.). The Nude Mouse in Oncology Research, pp. 317-326. Boca Raton, FL: CRC Press, 1991.
30. Berger, D. P., Winterhalter, B. R., and Fiebig, H. H. Chemotherapy: conventional agents. In: E. Boven and W. Winograd (eds.), The Nude Mouse in Oncology Research, pp. 165-184. Boca Raton, FL: CRC Press, 1991.
31. Bender, K., Steiert, A., Berger, P., and Fiebig, H. H. Characterization of 53 human tumor xenografts by polymorphic enzyme analysis. Contrib. Oncol., 42: 87-97, 1992.
32. Hiddemann, W., Von Bassewitz, D. B., Kleinemeir, H. J., Schulte-Brochterbeck, E., Hauss, J., Lingemann, B., Büchner, T., and Grundmann, E. DNA stemline heterogeneity in colorectal cancer. Cancer (Phila.), 58: 258-263, 1986.
33. Hamburger, A. W., and Salmon, S. E. Primary bioassay of human tumor stem cells. Science (Washington DC), 197: 461-463, 1977.
34. Von Hoff, D. D. In vitro predictive testing: the sulfonamide era. Int. J. Cell Cloning, 5: 179-190, 1987.
35. Scholz, C. C., Berger, D. P., Winterhalter, B. R., Henβ, H., and Fiebig, H. H. Correlation of drug response in patients and in the clonogenic assay with solid human tumor xenografts. Eur. J. Cancer, 26: 901-905, 1990.
36. Berger, D. P., Henβ, H., Winterhalter, B. R., and Fiebig, H. H. The clonogenic assay with human tumor xenografts: evaluation, predictive value and application for drug screening. Ann. Oncol., 1: 333-341, 1990.
37. Geahlen, R. L., Koonchanock, N. M., and McLaughlin, J. L. Inhibition of protein tyrosine kinase activity by flavonoids and related compounds. J. Nat. Prod., 52: 982-986, 1989.
38. 160 and Tyr 15. EMBO J., 11: 3995-4005, 1992.
39. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
40. Tam, S. W., Theodoras, A. M., Shay, J. W., Draetta, G. F., and Pagano, M. Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with CDK4 is required for cyclin D1 function in G1 progression. Oncogene, 9: 2663-2674, 1994.
41. Czech, J., Hoffmann, D., Naik, R., and Sedlacek, H. H. Antitumoral activity of the flavone L86-8275. Int. J. Oncol., 6: 31-36, 1995.
42. Paulson, D. F. Carcinoma of the prostate: the therapeutic dilemma. Annu. Rev. Med., 35: 341-372, 1984.
43. Gittes, R. F. Carcinoma of the prostate. N. Engl. J. Med., 324: 236-245, 1991.
44. Coleman, C. N., and Kaplan, I. D. Prostate cancer. Cancer (Phila.), 72: 305-309, 1993.